Kaveri Pohlman
Stock Analyst at Clear Street
(2.96)
# 1,364
Out of 5,154 analysts
31
Total ratings
38.71%
Success rate
3.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $11 → $20 | $15.47 | +29.28% | 1 | Mar 6, 2026 | |
| JANX Janux Therapeutics | Downgrades: Hold | $32 → $12 | $13.84 | -13.29% | 3 | Jan 20, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $12 | $1.63 | +636.20% | 1 | Dec 30, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $61 → $99 | $57.73 | +71.49% | 1 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $200 | $134.39 | +48.82% | 1 | Dec 5, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $14.05 | +77.94% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $13.30 | +57.89% | 1 | Nov 14, 2025 | |
| ZURA Zura Bio | Initiates: Buy | $18 | $6.97 | +158.25% | 1 | Nov 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $29 | $5.41 | +436.04% | 1 | Oct 22, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $32.97 | +39.52% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $23.43 | +36.58% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.23 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $27.06 | +73.69% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $15.74 | +90.60% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $11.32 | +235.69% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $4.59 | +8.93% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.37 | +483.94% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $41.55 | -35.01% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $22.11 | +216.60% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $5.99 | +100.33% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $4.68 | +70.94% | 2 | Jul 7, 2022 |
Erasca
Mar 6, 2026
Maintains: Buy
Price Target: $11 → $20
Current: $15.47
Upside: +29.28%
Janux Therapeutics
Jan 20, 2026
Downgrades: Hold
Price Target: $32 → $12
Current: $13.84
Upside: -13.29%
Palisade Bio
Dec 30, 2025
Initiates: Buy
Price Target: $12
Current: $1.63
Upside: +636.20%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $61 → $99
Current: $57.73
Upside: +71.49%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $200
Current: $134.39
Upside: +48.82%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $14.05
Upside: +77.94%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $13.30
Upside: +57.89%
Zura Bio
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $6.97
Upside: +158.25%
Sagimet Biosciences
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $5.41
Upside: +436.04%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $32.97
Upside: +39.52%
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $23.43
Upside: +36.58%
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.23
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $27.06
Upside: +73.69%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $15.74
Upside: +90.60%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $11.32
Upside: +235.69%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $4.59
Upside: +8.93%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.37
Upside: +483.94%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $41.55
Upside: -35.01%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $22.11
Upside: +216.60%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $5.99
Upside: +100.33%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.68
Upside: +70.94%